Jon Morikawa, MD
Obstetrics & Gynecology · Honolulu, HINPI 1952302200
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 68 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Amgen at 41.7% of the total. Reporting peaked in 2024 at $442 and has fallen 55.7% since, to $196 in 2025.
Across 68 payments — averaging $26.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$748
- Bayer$340
- AbbVie$226
- Organon$210
- Gen-probe Sales & Service, Inc.$102
- Roche Diagnostics Corporation$78
- plus $90 from 3 others
What the payments were for
- Food & beverage$1,794100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 29 | $748 |
| Bayer | 15 | $340 |
| AbbVie | 12 | $226 |
| Organon | 5 | $210 |
| Gen-probe Sales & Service, Inc. | 1 | $102 |
| Roche Diagnostics Corporation | 1 | $78 |
| Exeltis, USA Inc. | 3 | $59 |
| Merck | 1 | $18 |
| Evofem Biosciences, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,794 in reported general payments places this provider in the 80th percentile of 225 obstetrics & gynecology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 52 | $3,125 |
| Raloxifene Hcl | 21 | $3,091 |
| YuvafemEstradiol | 15 | $2,994 |
| Alendronate Sodium | 47 | $1,242 |
| ValacyclovirValacyclovir Hcl | 13 | $323 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Honolulu
- Richard McCartinHonolulu$32K
- Tricia WrightHonolulu$22K
- Bradley SakaguchiHonolulu$11K
- Harry YoshinoHonolulu$7K
- Lynette TsaiHonolulu$6K
- Franklin DaoHonolulu$5K
- Bliss KaneshiroHonolulu$5K
- Kurt YoshinoHonolulu$4K
- Cheryl Lynn RudyHonolulu$4K
- Gary KimotoHonolulu$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.